Our programs are designed to target and enable normal bile acid level modulation and treat diseases and disorders associated with irregularities in bile acid biology.
We are developing A4250 initially to treat patients with PFIC, a rare genetic liver disease.
We leverage our expertise in bile acid modulation to bring potentially transformative medicines to patients. For more information, read Albireo's Corporate Backgrounder.
January 3, 2018
December 29, 2017